ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

AMLX vs ACAD // NET PROFIT MARGIN

Amylyx Pharmaceuticals Inc. (NASDAQ) VS. ACADIA Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: AMLX 2 — ACAD 3
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AMLX VS. ACAD) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC AMLX ACAD SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 91.70% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% 7.90% -42.90 ACAD /roic <GO>
EV/EBITDA & P/E Valuation — 31.2x — TIE /valuation <GO>
Free Cash Flow Yield -3.43% 2.94% -6.37 ACAD /fcf-yield <GO>
Operating Margin — 9.80% — TIE /operating-margins <GO>
Net Profit Margin ACTIVE — 36.50% — TIE /net-margins <GO>
Revenue Growth (YoY) — 11.90% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 6.26 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 7/9 -4.00 ACAD /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 51.9 45.5 +6.37 AMLX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 8.5x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $3.60B $3.58B $21.1M AMLX /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR AMLX REV ACAD REV AMLX GROSS % ACAD GROSS % AMLX FCF ACAD FCF
FY 2025 $0 $1.07B — 91.7% -$123.5M $105.1M
FY 2024 $87.4M $957.8M 93.2% 91.5% -$167.8M $157.2M
FY 2023 $380.8M $726.4M — — $11.9M $16.7M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AMLX // BETA —
ACAD // BETA —